Mnpr-301-001- A Phase 2B/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing The Efficacy And Safety Of Clonidine Mucoadhesive Buccal Tablet To Placebo To Prevent Chemoradiotherapy-Induced Severe Oral Mucositis In Patients With Or
Posted Date: May 20, 2021
- Investigator: Vinita Takiar
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to evaluate the effectiveness of a new drug, clonidine HCl MBT, to prevent the onset of severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) who are being treated with chemoradiotherapy.
Criteria:
Must Have Diagnosed Squamous Cell Carcinoma Of The Oropharynx, Radiation Plan Must Include Delivery Of A Cumulative Dose Of 60-72 Gy, Ecog 0-1, Hpv +, No Prior Induction Chemotherapy For Treatment Of Current Malignancy, No Evidence Of A Concomitant Other Malignancy Or Prior Malignancy Within 2 Years. No Clinical Condition Or Infection That Would Make The Patient Unsuitable For The Study Or Unable To Comply With Study Requirements And Follow-Up Visits, No Current Treatment With Sultopride, Clonidine Hydrochloride (Eg, Catapres®), Pentoxifylline Or Pilocarpine
Keywords:
Oropharyngeal Cancer, Opc, Mucositis
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com